The role of polyamines in glucagon-like peptide-2 prevention of TPN-induced gut hypoplasia

被引:6
|
作者
Chance, WT [1 ]
Sheriff, S
Dayal, R
Friend, LA
Thomas, I
Balasubramaniam, A
机构
[1] VA Med Ctr, Med Res Serv, Cincinnati, OH USA
[2] Univ Cincinnati, Med Ctr, Dept Surg, Cincinnati, OH 45267 USA
关键词
DFMO; hypoplasia; small intestine; ornithine decarboxylase;
D O I
10.1016/j.peptides.2005.09.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Total parenteral. nutrition (TPN) of rats has been demonstrated to produce hypoplasia of gut mucosa, and to be associated with reduced immune response and elevated translocation of bacteria from gut to mesenteric lymph nodes, spleen and liver. Treatment of rats being maintained on TPN with the proglucagon fragment, glucagon-like peptide-2 (GLP-2), has been shown to totally prevent small intestine mucosal hypoplasia. In the present study, we found that depletion of polyamines with alpha-difluromethylornithine (DFMO) significantly reduced the efficacy of GLP-2 in preserving gut mucosa in rats maintained on TPN for 8 days. Co-infusion of GLP-2 with TPN prevented loss of protein and mucosa in duodenum, jejunum and ileum, but not in colon. Addition of DFMO to the infusate prevented the protective effects of GLP-2 in the duodenum and jejunum. In the jejunum, putrescine and spermicline were reduced in DFMO-treated rats, while the ileum exhibited reductions of these polyamines in rats infused with TPN or TPN plus GLP-2. DFMO infusion further reduced these polyamines in the ileum, while levels of spermine were increased. Concentrations of ornithine decarboxylase were elevated in jejunum of rats infused with TPN or TPN plus GLP-2, but were reduced significantly in DFMO-treated rats. These results suggest that normal levels of polyamines are necessary for the expression of GLP-2-induced hyperplasia. Differential effects of GLP-2 and DFMO across gut segments may relate to regional differences in proliferative and anti-apoptotic effects of the treatments. Published by Elsevier Inc.
引用
收藏
页码:883 / 892
页数:10
相关论文
共 50 条
  • [31] In vivo and in vitro degradation of glucagon-like peptide-2 in humans
    Hartmann, B
    Harr, MB
    Jeppesen, PB
    Wojdemann, M
    Deacon, CF
    Mortensen, PB
    Holst, JJ
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08): : 2884 - 2888
  • [32] Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2
    Drucker, Daniel J.
    Yusta, Bernardo
    ANNUAL REVIEW OF PHYSIOLOGY, VOL 76, 2014, 76 : 561 - 583
  • [33] Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function
    Brubaker, Patricia L.
    COMPREHENSIVE PHYSIOLOGY, 2018, 8 (03) : 1185 - 1210
  • [34] Glucagon-like peptide-2 increases BDNF expression in glia
    Yoshitake, Yumiko
    Iwai, Takashi
    Oka, Jun-Ichiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 124P - 124P
  • [35] Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats
    Chance, WT
    Sheriff, S
    McCarter, F
    Ogle, C
    JOURNAL OF BURN CARE & REHABILITATION, 2001, 22 (02): : 136 - 143
  • [36] Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2
    L'Heureux, MC
    Brubaker, PL
    ANNALS OF MEDICINE, 2001, 33 (04) : 229 - 235
  • [37] Distribution of glucagon-like peptide-2 in normal colonic tissue
    Caddy, G
    Johnston, C
    Ardill, J
    Pogue, K
    Collins, J
    Gardiner, K
    Watson, P
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2003, 38 (07) : 798 - 799
  • [38] Plasma glucagon-like peptide-2 in cats with chronic enteropathies
    Jugan, Maria C.
    Plattner, Brandon L.
    Ford, Alexandra K.
    Freilich, Leah
    Bieberly, Zackery
    Schermerhorn, Thomas
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2025, 27 (01)
  • [39] Current and potential therapeutic targets of glucagon-like peptide-2
    Austin, Kaori
    Markovic, Melanie A.
    Brubaker, Patricia L.
    CURRENT OPINION IN PHARMACOLOGY, 2016, 31 : 13 - 18
  • [40] Structure, measurement, and secretion of human glucagon-like peptide-2
    Hartmann, B
    Johnsen, AH
    Orskov, C
    Adelhorst, K
    Thim, L
    Holst, JJ
    PEPTIDES, 2000, 21 (01) : 73 - 80